Form 8-K Filing Summary for VolitionRx Limited

VolitionRx Limited entered into a waiver and consent agreement with Lind Global Asset Management XII LLC on May 21, 2026. This waiver addresses the Company's failure to comply with the Market Capitalization Covenant stipulated in the senior secured convertible promissory notes issued in May 2025 and January 2026. Lind has waived its rights to exercise remedies for this breach, including acceleration of debt or foreclosure on collateral. However, the failure to meet the covenant resulted in an additional payment of 10% of the outstanding principal amount for each note. The waiver allows Lind to convert all or a portion of the outstanding principal into the Company's common stock under specific conditions, including a conversion price discount and beneficial ownership limitations.